"This is who we were accredited by.."
Are you referring to this, paige?
ValiMed Receives Clean Bill of Health from TUV Rheinland of North America, Inc.
CDEX is Authorized to use TUV Mark on ValiMed
ROCKVILLE, MD.–April 10, 2006– CDEX, Inc. (CEXI.OB) announced today that it received permission from TUV Rheinland of North America Inc. (www.us.tuv.com) to apply the TUV mark to the ValiMed™1.0 system after completing an exhaustive three month product certification testing and quality assurance inspection of the manufacturing processes. The ValiMed medication verification system, which was developed by CDEX (www.cdex-inc.com) and is exclusively distributed by Baxa (www.baxa.com), gives clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying that medications are correctly compounded.
The notification from TUV marks the completion of exhaustive testing of the production model of the ValiMed system to verify compliance with applicable standards governing safety and emissions standards. The evaluation and testing was conducted to the same requirements and standards utilized by UL for the U.S. market, ULC for the Canadian market, CE for the European Union market, and CB Scheme for other international markets. The testing and evaluations were conducted in conjunction with Elliott Laboratories (elliottlabs.com) for compliance with Electromagnetic Testing for Electrical Equipment for Measurement, Control and Laboratory Use in accordance with EN 61326:1997 including A1: 1998 and A2: 2001. Safety tests and evaluations were conducted by TUV in accordance with IEC 61010-1 / EN 61010-1.
“The notification from TUV granting CDEX authorization to use the TUV mark on the ValiMed product represents the final phase in completing the first production run of our ValiMed system. Obtaining TUV certification for ValiMed represents a milestone achievement in the execution of our growth strategy and opens up significant world markets to ValiMed that go beyond the USA, Canada and the European Union. The efforts of the CDEX team and our manufacturing partner Mastek-InnerStep have resulted in the development and production of a unique life-safety product for use by healthcare professionals throughout the world,” said Jim Griffin, President and CEO of CDEX, Inc.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
AI
